Singer Kelly Key used her platform to bring attention to psoriasis on World Psoriasis Day, sharing her personal journey and encouraging others to learn more about the chronic skin condition. She will be hosting a live discussion with a dermatologist to discuss the challenges and care associated with psoriasis.
HC Wainwright has initiated coverage on Alumis Inc. (ALMS), a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases, with a Buy rating and a $30 price target. The firm is bullish on Alumis’ lead drug candidate, ESK-001, a TYK2 inhibitor currently in Phase 3 trials for psoriasis and Phase 2 trials for systemic lupus erythematosus. HC Wainwright believes ESK-001 possesses superior efficacy and selectivity compared to existing TYK2 inhibitors like Sotyktu (deucravacitinib), potentially capturing a significant market share.
